Viking Therapeutics, Inc. - COMMON STOCK (VKTX)

Historical Holders from Q2 2015 to Q3 2025

Symbol: VKTX on Nasdaq
Type / Class: Equity / COMMON STOCK
Shares outstanding: 113,177,462
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares, excl. options: 71,229,974
Holdings value: $1,871,916,119
% of all portfolios: 0.004%
Number of holders: 361
Number of buys: 187
Number of sells: -172
Average buys %: +0%
Average sells %: -0%

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of Viking Therapeutics, Inc. - COMMON STOCK (VKTX)

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
FMR LLC	5.1%	-40%	$151,689,488	-$105,010,859	5,772,050	-40.9%	FMR LLC	30 Sep 2025
BlackRock, Inc.	4.5%	-16%	$140,580,417	-$23,501,200	5,031,511	-14.3%	BlackRock, Inc.	31 Mar 2025

Institutional Holders of Viking Therapeutics, Inc. - COMMON STOCK (VKTX)

Period	Reported Shares, Excl. Options	Value, Excl. Options	Change	Puts Notional Value	Calls Notional Value	Price	Investors
2025 Q3	71,229,974	$1,871,916,119	-$130,106,510	$101,930,938	$189,541,858	$26.28	361
2025 Q2	76,160,666	$2,018,412,050	+$15,581,298	$87,521,080	$202,368,382	$26.5	386
2025 Q1	76,178,049	$1,840,349,819	-$233,469,532	$81,896,955	$198,321,640	$24.15	365
2024 Q4	82,015,393	$3,300,204,748	-$139,093,256	$151,019,622	$227,797,260	$40.24	405
2024 Q3	82,930,091	$5,250,281,341	+$233,179,536	$214,504,570	$361,128,906	$63.31	418
2024 Q2	80,417,324	$4,262,902,509	-$169,985,696	$157,407,894	$321,729,946	$53.01	383
2024 Q1	80,009,652	$6,559,940,568	+$370,099,401	$419,626,800	$580,402,379	$82	365
2023 Q4	76,419,206	$1,422,250,248	+$18,477,372	$20,608,714	$42,925,826	$18.61	193
2023 Q3	77,149,919	$854,043,342	+$8,950,047	$13,800,969	$29,324,290	$11.07	176
2023 Q2	74,791,312	$1,212,232,718	+$127,119,937	$23,893,128	$50,471,365	$16.21	192
2023 Q1	66,472,048	$1,107,025,988	+$548,273,938	$19,825,200	$42,434,499	$16.65	183
2022 Q4	34,003,932	$319,613,212	+$76,425,883	$3,223,040	$16,263,320	$9.4	126
2022 Q3	26,578,143	$72,293,762	-$1,008,538	$298,000	$389,000	$2.72	95
2022 Q2	26,701,115	$77,182,300	-$11,574,558	$200,000	$482,000	$2.89	97
2022 Q1	31,036,457	$93,177,398	-$16,601,086	$449,000	$456,000	$3	131
2021 Q4	36,199,999	$166,471,159	-$8,903,915	$593,000	$1,066,000	$4.6	133
2021 Q3	37,764,404	$237,662,655	-$338,194	$1,064,000	$3,477,000	$6.28	125
2021 Q2	37,867,341	$226,858,479	-$19,626,288	$1,208,000	$2,553,000	$5.99	133
2021 Q1	41,005,365	$259,319,860	+$20,962,700	$1,613,000	$4,389,000	$6.32	137
2020 Q4	37,734,744	$212,602,882	-$11,096,629	$1,952,000	$3,221,120	$5.63	136
2020 Q3	39,564,196	$230,268,043	-$4,355,775	$1,896,000	$5,184,000	$5.82	139
2020 Q2	40,230,477	$290,007,852	+$8,150,488	$2,239,000	$9,399,000	$7.21	133
2020 Q1	39,356,943	$184,161,493	-$8,373,431	$1,540,000	$4,124,000	$4.68	130
2019 Q4	39,771,461	$318,974,059	-$5,272,426	$7,786,000	$12,307,000	$8.02	134
2019 Q3	40,703,230	$280,039,135	-$33,395,341	$5,523,000	$14,877,000	$6.88	139
2019 Q2	45,087,675	$374,231,879	-$7,341,449	$9,191,000	$16,525,000	$8.3	150
2019 Q1	45,718,634	$454,329,676	-$4,966,661	$13,168,000	$23,499,000	$9.94	158
2018 Q4	46,936,233	$359,030,721	-$11,223,062	$4,365,000	$5,826,000	$7.65	159
2018 Q3	43,213,947	$752,787,195	+$280,535,030	$21,245,000	$21,141,000	$17.42	146
2018 Q2	31,601,829	$299,901,220	+$126,057,321	$4,902,000	$4,874,000	$9.49	115
2018 Q1	20,905,622	$91,354,000	+$50,569,356	$115,000	$622,000	$4.37	62
2017 Q4	9,329,591	$37,876,000	+$30,074,098			$4.06	32
2017 Q3	2,021,286	$3,851,000	+$1,491,357			$1.91	16
2017 Q2	1,568,425	$1,692,000	+$856,257			$1.08	11
2017 Q1	769,601	$1,124,000	+$226,915			$1.46	10
2016 Q4	636,030	$757,000	-$869,302			$1.19	11
2016 Q3	1,209,905	$1,701,000	+$495,636			$1.41	13
2016 Q2	860,090	$1,083,000	+$1,026,020			$1.26	12
2016 Q1	44,443	$65,000	-$25,998			$1.53	6
2015 Q4	41,278	$140,000	-$14,614			$3.36	5
2015 Q3	43,175	$252,000	-$77,596			$5.83	6
2015 Q2	54,005	$384,000	+$384,000			$7.1	5